SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
A Citarella, A Scala, A Piperno, N Micale - Biomolecules, 2021 - mdpi.com
The uncontrolled spread of the COVID-19 pandemic caused by the new coronavirus SARS-
CoV-2 during 2020–2021 is one of the most devastating events in the history, with …
CoV-2 during 2020–2021 is one of the most devastating events in the history, with …
Drug combinations as a first line of defense against coronaviruses and other emerging viruses
The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-
equipped for future pandemics. While unprecedented strides have been made developing …
equipped for future pandemics. While unprecedented strides have been made developing …
Racial and ethnic discrepancy in pulse oximetry and delayed identification of treatment eligibility among patients with COVID-19
Importance Pulse oximetry guides triage and therapy decisions for COVID-19. Whether
reported racial inaccuracies in oxygen saturation measured by pulse oximetry are present in …
reported racial inaccuracies in oxygen saturation measured by pulse oximetry are present in …
Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice
E Mozaffari, A Chandak, RL Gottlieb… - Clinical Infectious …, 2023 - academic.oup.com
Background Immunocompromised patients are at high risk of severe coronavirus disease
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …
[PDF][PDF] Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational …
E Mozaffari, A Chandak, Z Zhang, S Liang… - Clin Infect …, 2021 - scholar.archive.org
Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-
hospital all-cause mortality in a lar Page 1 © The Author(s) 2021. Published by Oxford University …
hospital all-cause mortality in a lar Page 1 © The Author(s) 2021. Published by Oxford University …
Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large …
E Mozaffari, A Chandak, Z Zhang… - Clinical Infectious …, 2022 - academic.oup.com
Background Remdesivir (RDV) improved clinical outcomes among hospitalized patients with
coronavirus disease 2019 (COVID-19) in randomized trials, but data from clinical practice …
coronavirus disease 2019 (COVID-19) in randomized trials, but data from clinical practice …
Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population …
T Benfield, J Bodilsen, C Brieghel… - Clinical Infectious …, 2021 - academic.oup.com
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …
Remdesivir significantly reduces SARS‐CoV‐2 viral load on nasopharyngeal swabs in hospitalized patients with COVID‐19: A retrospective case–control study
A Biancofiore, A Mirijello, MA Puteo… - Journal of Medical …, 2022 - Wiley Online Library
Remdesivir is a broad‐spectrum antiviral agent able to inhibit the RNA polymerase of SARS‐
CoV‐2. At present, studies focusing on the effect of remdesivir on viral load (VL) are few and …
CoV‐2. At present, studies focusing on the effect of remdesivir on viral load (VL) are few and …
Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study
Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis
This network meta-analysis (NMA) assessed the efficacy of remdesivir in hospitalized
patients with COVID-19 requiring supplemental oxygen. Randomized controlled trials of …
patients with COVID-19 requiring supplemental oxygen. Randomized controlled trials of …